New Hologic CEO aims for Dx revenue growth over sale option

On the way in the door as the new CEO of Hologic ($HOLX), Stephen MacMillan said he would oversee further growth of the women's diagnostic medical imaging and surgical products company, despite Hologic's recent efforts to reorganize. With the guiding hand of Carl Icahn, who recently grabbed 12.6% of Hologic's shares, the M&A option was rumored to be on the table, but it looks as if the company will first aim to boost revenue if MacMillan, the former CEO of Stryker ($SYK), can make it happen. More from FierceDiagnostics

Suggested Articles

The FDA has cleared its first fully disposable duodenoscope, following years of reports of infections being transmitted between patients.

OR-focused AI provider Caresyntax has garnered $45.6 million in new funding and picked up a data analytics firm to broaden its footprint.

A study of Foundation Medicine’s FoundationOne liquid biopsy test found it was able to predict the risk that a person’s breast cancer would return.